Multilayered Si/RGO anode nanostructures, featuring alternating Si nanoparticle (NP) and RGO layers, good mechanical stability, and high electrical conductivity, allow Si NPs to easily expand between RGO layers, thereby leading to high reversible capacity up to 2300 mAh g(-1) at 0.05 C (120 mA g(-1) ) and 87% capacity retention (up to 630 mAh g(-1) ) at 10 C after 152 cycles.

No abstract

No abstract

LiFePO 4 /Li 4/3 Ti 5/3 O 4 Li-ion cells have been investigated by many groups and their behavior in standard electrolytes such as 1 M LiPF 6 ethylene carbonate: diethyl carbonate ͑EC:DEC͒ is well known. Here we report on the behavior of these cells with 2,5-ditertbutyl-1,4-dimethoxybenzene added to the electrolyte as a redox shuttle additive to prevent overcharge and overdischarge. We explore methods to increase the current-carrying capacity of the shuttle and explore the heating of practical cells during extended overcharge. The solubility of 2,5-ditertbutyl-1,4-dimethoxybenzene was determined as a function of salt concentration in lithium bis-oxolatoborate-͑LiBOB͒ and LiPF 6 -containing electrolytes based on propylene carbonate ͑PC͒, EC, DEC, and dimethyl carbonate ͑DMC͒ solvents. Concentrations of 2,5-ditertbutyl-1,4-dimethoxybenzene up to 0.4 M can be obtained in 0.5 M LiBOB PC:DEC ͑1:2 by volume͒. Coin-type test cells were tested for extended overcharge protection using an electrolyte containing 0.2 M 2,5-ditertbutyl-1,4-dimethoxybenzene in 0.5 M LiBOB PC:DEC. Sustained overcharge protection at a current density of 2.3 mA/cm 2 was possible and hundreds of 100% shuttle-protected overcharge cycles were achieved at current densities of about 1 mA/cm 2 . The diffusion coefficient of the shuttle molecule in this electrolyte was determined to be 1.6 ϫ 10 −6 cm 2 /s from cyclic voltammetry and also from measurements of the shuttle potential vs. current density. The power produced during overcharge was measured using isothermal microcalorimetry and found to be IV as expected, where I is the charging current and V is the cell terminal voltage during shuttle-protected overcharge. Calculations of the temperature of 18650-sized Li-ion cells as a function of time during extended shuttle-protected overcharge at various C-rates are presented. These show that Li-ion cells need external cooling during extended shuttle-protected overcharge if currents exceed about C/5 rates.

Fifty eight aromatic organic molecules were screened as chemical shuttles to provide overcharge protection for LiFePnormalO4 /graphite and LiFePnormalO4∕normalLi4∕3normalTi5∕3normalO4 Li-ion cells. The majority of the molecules were based on methoxybenzene and on dimethoxybenzene with a variety of ligands added to explore their effect. The added ligands affect the redox potential of the molecules through their electron-withdrawing effect and affect the stability of the radical cation. Of all the molecules tested, only 2,5-di-tert-butyl-1,4-dimethoxybenzene shows an appropriate redox potential of 3.9V vs Li∕normalLi+ and long-term stability during extended abusive overcharge totaling over 300cycles of 100% overcharge per cycle. The reasons for the success of this molecule are explored.

No abstract

Long non-coding RNAs (lncRNAs) play important roles in diverse biological processes, such as transcriptional regulation, cell growth and tumorigenesis. However, little is known about whether lncRNA-GAS5 (growth arrest-specific 5) regulates bladder cancer progression. In the present study, we found that the GAS5 expression is commonly downregulated in bladder cancer cell lines and human specimens. Knockdown of GAS5 promotes bladder cancer cell proliferation, whereas forced expression of GAS5 suppresses cell proliferation. We further demonstrated that knockdown of GAS5 increases CDK6 mRNA and protein levels in bladder cancer cells. Expectedly, GAS5 inhibition induces a significant decrease in G0/G1 phase and an obvious increase in S phase. Gain-of-function and loss-of-function studies showed that GAS5 inhibits bladder cancer cell proliferation, at least in part, by regulating CDK6 expression.ConclusionsDownregulated GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6, and thus may be helpful in the development of effective treatment strategies against bladder cancer.

The enumeration of circulating tumor cells (CTCs) provides important prognostic values in patients with metastatic breast cancer. Recent studies indicate that individual CTCs form clusters and these CTC-clusters play an important role in tumor metastasis. We aimed to assess whether quantification of CTC-clusters provides additional prognostic value over quantification of individual CTCs alone. In 115 prospectively enrolled advanced-stage (III and IV) breast cancer patients, CTCs and CTC-clusters were counted in 7.5 ml whole blood using the CellSearch system at baseline before first-line therapy. The individual and joint effects of CTC and CTC cluster counts on patients' progression-free survival (PFS) were analyzed using Cox proportional hazards modeling. Of the 115 patients, 36 (31.3 %) had elevated baseline CTCs (≥5 CTCs/7.5 ml) and 20 (17.4 %) had CTC-clusters (≥2 CTCs/7.5 ml). Patients with elevated CTCs and CTC-clusters both had worse PFS with a hazard ratio (HR) of 2.76 [95 % confidence interval (CI) 1.57-4.86, P log-rank = 0.0005] and 2.83 (1.48-5.39, P log-rank = 0.001), respectively. In joint analysis, compared with patients with <5 CTCs and without CTC-clusters, patients with elevated CTCs but without clusters, and patients with elevated CTCs and with clusters, had an increasing trend of progression risk, with an HR of 2.21 (1.02-4.78) and 3.32 (1.68-6.55), respectively (P log-rank = 0.0006, P trend = 0.0002). The additional prognostic value of CTC-clusters appeared to be more pronounced in patients with inflammatory breast cancer (IBC), the most aggressive form of breast cancer with the poorest survival. Baseline counts of both individual CTCs and CTC-clusters were associated with PFS in advanced-stage breast cancer patients. CTC-clusters might provide additional prognostic value compared with CTC enumeration alone, in patients with elevated CTCs.